Showing 3571-3580 of 4164 results for "".
- Heidelberg Engineering Names New Scientific Directorhttps://modernod.com/news/heidelberg-engineering-names-new-scientific-director/2478603/Charles Reisman has joined Heidelberg Engineering’s global management team as Scientific Director. In this newly created role, he will be responsible for the clinical research plan that directly feeds into the product development pipeline. Mr. Reisman is an accomplished clinical validation
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- AGTC Announces Productivity and Quality Enhancement To Its Proprietary Manufacturing Processhttps://modernod.com/news/agtc-announces-productivity-and-quality-enhancement-to-its-proprietary-manufacturing-process/2477916/Applied Genetic Technologies Corporation (AGTC) provided an update on the productivity and quality improvements made in its proprietary manufacturing platform that is currently being used to create clinical trial material for the company’s planned pivotal clinical trials in X-linked retinitis pig
- Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapieshttps://modernod.com/news/regeneron-ceo-manufacturing-not-up-to-snuff-for-covid-19-vaccines-therapies/2477753/Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman i
- Adverum Biotechnologies Reports Positive Interim Data of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-reports-positive-interim-data-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477705/Adverum Biotechnologies announced new interim clinical data from Cohorts 1-3 of the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD) and provided
- Retina Specialists Share How They Are Adjusting to COVID-19https://modernod.com/news/retina-specialists-share-how-they-are-adjusting-to-covid-19/2477416/As the novel coronavirus outbreak continues to spread in the United States, retina clinics—who often see older patients who are more at risk of virus complications—are making a number of adjustments. Rishi P. Singh, MD, staff physician at the Cole Eye Institute at the Cleveland Clinic, whe
- Ocular Therapeutix Presents Data Demonstrating a Reduction in IOP in Patients Treated with OTX-TIChttps://modernod.com/news/ocular-therapeutix-presents-data-demonstrating-a-reduction-in-iop-in-patients-treated-with-otx-tic/2477290/Ocular Therapeutix presented data on OTX-TIC, a long acting travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension. Data from this phase 1 clinical trial demonstrated a clinically-meaningful reduction in IOP for up to 18 months in the
- Adverum Reports New Interim Data from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-reports-new-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477288/Adverum Biotechnologies announced new interim clinical data from the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macu
- ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-announces-first-patient-dosed-in-phase-1-2-aurora-trial-of-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477159/ProQR Therapeutics announced the first patient dosed in the phase 1/2 Aurora clinical trial of QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP). Initial data from the study are expected in 2021. “From previous clinical trials we have seen that RNA therapies can be a
- Optina Diagnostics and Wagner Macula Retina Center to Conduct a Study to Identify the Causes of Memory Loss Through Eye Diagnosticshttps://modernod.com/news/optina-diagnostics-and-wagner-macula-retina-center-will-collaborate-to-conduct-a-clinical-study-to-identify-the-causes-of-memory-loss-through-eye-diagnostics/2477076/Optina Diagnostics and Wagner Macula Retina Center are entering into a collaboration agreement to conduct a clinical study for the advancement of Optina’s Retinal Deep Phenotyping platform. This collaboration will lay the groundwork for Optina’s future pivotal clinical trial. &